eligard 7.5 mg
kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 7.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
goserelin cell pharm 3,6 mg implantat
zoladex 3.6 milligram implant
b & s healthcare - goserelin acetate - implant - 3.6 milligram - gonadotropin releasing hormone analogues
zoladex 3.6 mg depot implant in pre-filled syringe
astrazeneca uk ltd parklands alderley park macclesfield cheshire - goserelin acetate - implant in pre-filled syringe - 3.6 mg goserelin acetate per depot - hormones and related agents:
zoladex la 10.8 mg injection implant in pre-filled syringe
astrazeneca uk ltd parklands alderley park macclesfield cheshire - goserelin acetate - implant in pre-filled syringe - each injection contains 10.8 mg goserelin acetate - hormones and related agents:
zolacos cp
goserelin; bicalutamide -
eligard 45 mg powder and solvent for solution for injection
astellas pharma co. ltd - leuprorelin acetate - powder and solvent for solution for injection - 45 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin
eligard 22.5 mg, powder and solvent for solution for injection
astellas pharma co. ltd - leuprorelin acetate - powder and solvent for solution for injection - 22.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin
eligard 7.5 mg powder and solvent for solution for injection
astellas pharma co. ltd - leuprorelin acetate - powder and solvent for solution for injection - 7.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin
leuprorelin sandoz
sandoz new zealand limited - leuprorelin acetate 3.78mg equivalent to 3.6 mg leuprorelin - subcutaneous implant - 3.6 mg - active: leuprorelin acetate 3.78mg equivalent to 3.6 mg leuprorelin excipient: polyglactin - palliative treatment of patients with advanced, hormone-dependent prostate carcinoma